However, Paul Hudson, CEO of Sanofi, one of the world's leading biopharmaceutical companies, says executives may need to rein ...

There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to ...

Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare disease targets.

In November 2021, Sanofi made a similar – but not its first – investment in AI, taking a $180 million equity stake in Franco-US start-up Owkin with another $90 million in funding for a ...

Today, Formation Bio, together with OpenAI and Sanofi, introduced Muse, an advanced AI-powered tool developed to accelerate and improve drug development by optimizing patient recruitment for clinical ...

The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...

Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today ...

Vera Therapeutics appointed Amgen and Seagen alum Matt Skelton as EVP of commercial. Frank Lane was appointed SVP and head of ...

“The future in this space is limitless,” said Frenehard. How AI is Enhancing Research and Development at Sanofi AI is being used across the value chain at Sanofi to get treatments to patients ...

SandboxAQ's Quantitative AI models aim to understand human biology ... The application with Sanofi focused on biomarker identification is very exciting as it increases our reach into later ...